pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
pharmaphorum

Company Profile: Recursion

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Seeking Alpha

Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...
InfoQ

MIT's Recursive Language Models Improve Performance on Long-Context Tasks

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
IEEE

Blockwise Recursive Moore–Penrose Inverse for Network Learning

Abstract: Training neural networks with the Moore–Penrose (MP) inverse has recently gained attention in view of its noniterative training nature. However, a significant drawback of learning based on ...
IEEE

A Robust and Regularized Algorithm for Recursive Total Least Squares Estimation

Abstract: In this letter, a novel recursive total least squares (RTLS) algorithm that is grounded in a constrained Lagrange optimization of the errors-in-variables model is presented. The proposed ...